Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Krishna S Pothugunta

Internal Medicine Troy, MI Medical Doctor

NPI 1285869982 CMS profile 799231

4600 Investment Dr, Suite 290, Troy, MI 48098

Open in the dashboard

General payments

$6,752

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krishna S Pothugunta of Troy, MI is reported in the CMS Open Payments database as having received $6,752 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,211 54
2024 General $1,266 62
2023 General $895 51
2022 General $990 51
2021 General $741 37
2020 General $449 19
2019 General $1,201 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krishna S Pothugunta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Krishna S Pothugunta were reported at $1,211. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Krishna S Pothugunta Internal Medicine median Middle half National median
2019 $1,201 $159 $48–$570 $163
2020 $449 $119 $33–$402 $114
2021 $741 $135 $37–$521 $132
2022 $990 $141 $42–$496 $149
2023 $895 $149 $45–$519 $160
2024 $1,266 $154 $47–$537 $164
2025 $1,211 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $614 31 payments
  2. AstraZeneca Pharmaceuticals LP $589 29 payments
  3. Otsuka America Pharmaceutical, Inc. $443 18 payments
  4. Mallinckrodt Hospital Products Inc. $443 18 payments
  5. Retrophin, Inc. $419 26 payments
  6. Aurinia Pharma U.S., Inc. $372 14 payments
  7. Relypsa, Inc. $327 20 payments
  8. GlaxoSmithKline, LLC. $310 23 payments
  9. Alexion Pharmaceuticals, Inc. $294 13 payments
  10. Calliditas Therapeutics US Inc. $264 14 payments
  11. Other $2,676 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,487 314 payments
  2. Education $265 12 payments
Products named General payments · program years 2019–2025
  1. ACTHAR Immunology $443 18 payments
  2. LUPKYNIS $372 14 payments
  3. LOKELMA $297 14 payments
  4. BENLYSTA $289 22 payments
  5. FARXIGA $269 14 payments
  6. Kerendia $262 13 payments
  7. JYNARQUE $243 12 payments
  8. ACTHAR Autoimmune And Rare Disease $225 9 payments
  9. TAVNEOS $211 10 payments
  10. TARPEYO $210 11 payments
  11. Other $3,535 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,253

Median for Nephrology: 954

Drug cost

$152,395

Median for Nephrology: $127,050

Branded share of claims

10.1%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 40 $50,715
Lokelma Sodium Zirconium Cyclosilicate Brand 37 $26,734
Calcitriol Generic 651 $13,473
Farxiga Dapagliflozin Propanediol Brand 14 $11,710
Eliquis Apixaban Brand 11 $10,769
Cinacalcet Hcl Generic 60 $7,735
Potassium Citrate Er Potassium Citrate Brand 67 $6,519
Bumetanide Generic 60 $2,789
Sevelamer Carbonate Generic 14 $1,965
Allopurinol Generic 98 $1,661

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$189,849

Medicare's payments for the services billed

Medicare patients

526

Average age 75

Services billed

2,478

279 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 60%
Ischemic heart disease 60%
Arthritis 56%
Heart failure 46%
Atrial fibrillation 38%
Depression 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $135
$135 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $114
$114 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $108
$108 40 —
IBSRELA
  • Ardelyx, Inc. $88
$88 — —
TAVNEOS
  • Amgen Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record